Advertisement
Cancer
Subscribe to Cancer
View Sample

FREE Email Newsletter

Nanofiber mesh fights cancerous tumors

July 3, 2013 9:20 am | News | Comments

A research team at the National Institute for Materials Science in Japan has developed a new nanofiber mesh which is capable of simultaneously performing thermotherapy and chemotherapy of tumors. Using this new mesh, the team succeeded in efficiently inducing natural death of epithelial cancer cells.

Cancerous traffic jams

July 2, 2013 8:41 am | News | Comments

Evidence is mounting that the development and spread of cancer, long attributed to gene expression and chemical signaling gone awry, involves a biomechanical component as well. Researchers at Lawrence Berkeley National Laboratory have added to this body of evidence by demonstrating that the malignant activity of a critical cellular protein system can arise from what essentially are protein traffic jams.

Shape-shifting nanoparticles flip from sphere to net in response to tumor signal

May 29, 2013 8:10 am | News | Comments

Scientists at the University of California, San Diego have designed tiny spherical particles to float easily through the bloodstream after injection, then assemble into a durable scaffold within diseased tissue. An enzyme produced by a specific type of tumor can trigger the transformation of the spheres into net-like structures that accumulate at the site of a cancer.

Advertisement

Researchers develop radioactive nanoparticles that target cancer cells

May 22, 2013 9:09 am | News | Comments

Scientists in Missouri have successfully created nanoparticles made of a radioactive form of the element lutetium. By covering these particles with gold shells and attaching targeting agents, they have a tool that can seek out dangerous secondary lymphoma tumors. They recently demonstrated the nanoparticles can find the tumors without attaching to or damaging healthy cells.

Protected data cloud to analyze cancer data

May 20, 2013 9:16 am | News | Comments

The University of Chicago has recently  launched the first secure cloud-based computing system that enables researchers to access and analyze human genomic cancer information, such as the The Cancer Genome Atlas, without the costly and cumbersome infrastructure normally needed to download and store massive amounts of data.

United Tech donates $3M for Yale cancer research

May 15, 2013 1:20 pm | by The Associated Press | News | Comments

Aerospace conglomerate United Technologies Corp. says it's donated $3 million to establish an endowed professorship at the Yale Cancer Center in New Haven. Lieping Chen will be the first United Technologies Corp. Professor in Cancer Research and is known for research leading to clinical trials of new cancer drugs that harness the body's immune system to fight cancer.

Study identifies key protein for cell death

May 14, 2013 10:49 am | by Anne Trafton, MIT News Office | News | Comments

When cells suffer too much DNA damage, they are usually forced to undergo programmed cell death, or apoptosis. However, cancer cells often ignore these signals, flourishing even after chemotherapy drugs have ravaged their DNA. A new finding may offer a way to overcome that resistance: A team has identified a key protein involved in an alternative death pathway known as programmed necrosis.

Huge drug cost disparities seen in health overhaul

May 13, 2013 3:11 am | by RICARDO ALONSO-ZALDIVAR - Associated Press - Associated Press | News | Comments

Cancer patients could face high costs for medications under President Barack Obama's health care law, industry analysts and advocates warn. Where you live could make a huge difference in what you'll pay. To try to keep premiums low, some states are allowing insurers to charge patients a hefty share of the cost for expensive medications used to treat cancer, multiple sclerosis, rheumatoid arthritis, and other life-altering chronic diseases.

Advertisement

Eli Lilly ends development of lymphoma drug

May 10, 2013 1:06 pm | by The Associated Press | News | Comments

Eli Lilly and Co. said Friday it will stop development of an experimental cancer drug after it failed in a late-stage clinical trial. The company was studying enzastaurin as a treatment for diffuse large B-cell lymphoma, a cancer that affects a type of white blood cell. Lilly said patients who were treated with enzastaurin did not survive longer than patients treated with a placebo.

Turn out the light: Switch determines cancer cell fate

May 3, 2013 8:10 am | by Anne Ju, Cornell University | News | Comments

Like picking a career or a movie, cells have to make decisions—and cancer results from cells making wrong decisions. At the cellular level, wrong decisions can be made right. A team has discovered that colon cancer stem cells, a particularly malignant population of cancer cells, are able to switch between the decision to proliferate or to remain constant—and this “switch” is controlled by a little-studied molecule called microRNA.

Computer algorithms find genetic cancer networks

May 2, 2013 10:44 am | News | Comments

Researchers at Washington University in St. Louis, using powerful algorithms developed by computer scientists at Brown University, have assembled the most complete genetic profile yet of acute myeloid leukemia, an aggressive form of blood cancer.

Decoded: Molecular messages that tell cancer to spread

May 2, 2013 7:53 am | News | Comments

Cancer cells are wily, well-traveled adversaries, constantly side-stepping treatments to stop their spread. But, for the first time, scientists at the University of Michigan have decoded the molecular chatter that ramps certain cancer cells into overdrive and can cause tumors to metastasize throughout the body.

Team finds markers related to ovarian cancer survival, recurrence

April 29, 2013 1:34 pm | News | Comments

Researchers at the University of Illinois have identified biomarkers that can be used to determine ovarian cancer survival and recurrence, and have shown how these biomarkers interact with each other to affect these outcomes. The team used data from the Cancer Genome Atlas, which contains information about ovarian cancer patients’ age, survival, cancer recurrence, treatment, tumor stage, tumor grade, and genomic expression.

Advertisement

Tests on cancer cells shows them as “squishy”, yet tactically strong

April 29, 2013 8:06 am | News | Comments

To get a better understanding of metastasis, more than 95 graduate students, post docs and professors in a variety of laboratories across the U.S. subjected two cell lines to a battery of tests and measurements using more than 20 different techniques. The work has enabled a comprehensive cataloging and comparison of the physical characteristics of non-malignant and metastatic cells.

Physicists, biologists unite to expose how cancer spreads

April 29, 2013 8:03 am | News | Comments

Cancer cells that can break out of a tumor and invade other organs are more aggressive and nimble than nonmalignant cells, according to a new multi-institutional nationwide study. These cells exert greater force on their environment and can more easily maneuver small spaces.

Nanodiamonds could improve effectiveness of breast cancer treatment

April 16, 2013 7:50 am | News | Comments

Doctors have begun to categorize breast cancers into four main groups according to the genetic makeup of the cancer cells. Which category a cancer falls into generally determines the best method of treatment. But cancers in one of the four groups—called "basal-like" or "triple-negative" breast cancer (TNBC)—have been particularly tricky to treat. Researchers have developed a potential treatment for TNBC that uses nanodiamonds.

Study reveals how melanoma evades chemotherapy

April 9, 2013 11:04 pm | News | Comments

Nitric oxide (NO), a gas with many biological functions in healthy cells, can also help some cancer cells survive chemotherapy. A new study from Massachusetts Institute of Technology (MIT) reveals one way in which this resistance may arise, and raises the possibility of weakening cancer cells by cutting off their supply of NO.

Cancer-killing treatment has no side effects

April 4, 2013 9:21 am | News | Comments

Cancer painfully ends more than 500,000 lives in the United States each year, according to the Centers for Disease Control and Prevention. The scientific crusade against cancer recently achieved a victory under the leadership of University of Missouri Curators’ Professor M. Frederick Hawthorne. Hawthorne’s team has developed a new form of radiation therapy that successfully put cancer into remission in mice. This innovative treatment produced none of the harmful side-effects of conventional chemo and radiation cancer therapies.

Scientists find new gene markers for cancer risk

March 27, 2013 2:37 pm | by Malcolm Ritter, AP Science Writer | News | Comments

A huge international effort involving more than 100 institutions and genetic tests on 200,000 people has uncovered dozens of signposts in DNA that can help reveal further a person's risk for breast, ovarian or prostate cancer, scientists reported Wednesday. The potential payoff for ordinary people is mostly this: Someday there may be genetic tests that help identify women with the most to gain from mammograms, and men who could benefit most from PSA tests and prostate biopsies.

Scientists find new gene markers for cancer risk

March 27, 2013 12:28 pm | by MALCOLM RITTER - AP Science Writer - Associated Press | News | Comments

A huge international effort involving more than 100 institutions and genetic tests on 200,000 people has uncovered dozens of signposts in DNA that can help reveal further a person's risk for breast, ovarian, or prostate cancer, scientists reported Wednesday.

Nanotechnology research study turns brain tumors blue

March 27, 2013 11:46 am | News | Comments

Researchers from Georgia Tech and Children's Healthcare of Atlanta have developed a technique that assists in identifying tumors from normal brain tissue during surgery by staining tumor cells blue. The technique could be critically important for hospitals lacking sophisticated equipment in preserving the maximum amount of normal tissue and brain function during surgery.

Scientists find chemical that might control cell behavior

March 14, 2013 10:09 am | News | Comments

Most people who are killed by cancer are victims of the spread of the original cancerous tumor, which is why researchers vigorously search for drugs that can prevent metastases. In a finding that could help accelerate that effort, researchers have found a chemical compound that appears to control cell migration and adhesion, two important characteristics of metastatic cancer cells.

FDA approves imaging drug for cancer lymph nodes

March 13, 2013 1:45 pm | by The Associated Press | News | Comments

The Food and Drug Administration has approved a new imaging drug to help doctors locate lymph nodes in patients with breast cancer and skin cancer. The drug Lymphoseek from Navidea Biopharmaceuticals Inc. is a radioactive imaging agent that is intended to help determine if breast cancer or melanoma has spread to a patient's lymph nodes.

Rapid cancer detection built on a chip

March 8, 2013 3:39 pm | News | Comments

Early detection is vital for the effective treatment of cancer. In many cases, tell-tale biomarkers are present in the bloodstream long before outward symptoms become apparent. The development of an inexpensive and rapid point-of-care diagnostic test capable of spotting such early biomarkers of disease could save many lives. A research team in Japan working on developing such a test has now produced their most sensitive microRNA detector yet.

Traceable nanoparticles may be the next weapon in cancer treatment

March 5, 2013 8:58 am | by Karin Söderlund Leifler and Peter Larsson, KTH Royal Institute of Technology | News | Comments

Therapeutic and diagnostic in function, so-called “theranostic” particles have been developed by a team in Sweden. These small particles can be loaded with medicine and could be a future weapon for cancer treatment. Because the particles can be seen in magnetic resonance images, they are traceable.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading